Salvatore Brugaletta: Is Twelve Months of DAPT Still Too Long After ACS?
Salvatore Brugaletta, Associate Professor of Medicine at University of Barcelona, shared on LinkedIn about a recent article he and his colleagues co-authored, published in BMJ Heart, adding:
”Twelve months DAPT starts to be too long as compared to a strategy of short DAPT in ACS patients.
While earlier aspirin discontinuation may be associated with greater net clinical benefit owing to reduced bleeding, 3- month DAPT may be associated with more favourable ischaemic outcomes, underscoring the importance of individualising DAPT duration according to bleeding and ischaemic risk.”
Title: Optimal timing of aspirin discontinuation after acute coronary syndrome treated with percutaneous coronary intervention: a systematic review and meta-analysis
Authors: Kamil Bujak, Claudio Laudani, Riccardo Rinaldi, Paweł Łajczak, Mariusz Gąsior, Natalia Pawlas, Luis Ortega-Paz, Manel Sabate, Salvatore Brugaletta
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 29, 2026, 03:53Nahrwan Masaoodi: Iron Deficiency Can Exist Without Anemia
-
Sep 29, 2026, 03:38Muhammad Yousaf: Iron Deficiency Beyond Diet
-
Sep 29, 2026, 03:21Parvez Ahmed Chowdhury: Synthesizing Aspirin in the Organic Chemistry Lab
-
Sep 29, 2026, 03:12Ahmed Hamandi: Building the Future of Hematopoietic Transplantation in Iraq
-
Sep 29, 2026, 03:09M V Chandrakanth: Aspirin in CRC – Old Drug, New Precision Oncology?
-
Sep 29, 2026, 03:07Caroline Pothet: Advancing Treatment Development in Sickle Cell Disease and Thalassaemia
-
Sep 29, 2026, 02:53Astha Jain: Thalassemia Care Through a Public Health Lens
-
Sep 29, 2026, 02:50Emma Groarke: Starting a New Career Path in Homeland
-
Sep 28, 2026, 19:14Aditya Sharma: An Outstanding Start to the Final Day of VSS 2026!